Detection of an ALK fusion in colorectal carcinoma by hybrid capture-based assay of circulating tumor DNA

Oncologist

Volumn 22, Issue 7, 2017, Pages 774-779

  Lai, Andrea Z ^a   Schrock, Alexa B ^a   Erlich, Rachel L ^a   Ross, Jeffrey S ^a   Miller, Vincent A ^a   Yakirevich, Evgeny ^b   Ali, Siraj M ^a   Braiteh, Fadi ^c,d  

^a FOUNDATION MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c Division of Hematology and Medical Oncology   (United States)

^d UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

ALK fusion; Circulating tumor DNA; Colorectal cancer; Genomic profiling

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINATE CALCIUM; HYBRID PROTEIN; OXALIPLATIN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; CALMODULIN BINDING PROTEIN; CIRCULATING TUMOR DNA; MEMBRANE PROTEIN; NERVE PROTEIN; PROTEIN TYROSINE KINASE; STRN PROTEIN, HUMAN;

ADULT; ARTICLE; CASE REPORT; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; COLONOSCOPY; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DNA FINGERPRINTING; FEMALE; GENE MUTATION; GENOTYPE; HEMICOLECTOMY; HUMAN; MIDDLE AGED; ONCOLOGIST; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; WHOLE EXOME SEQUENCING; COLORECTAL TUMOR; GENE FUSION; GENETIC PROCEDURES; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

CALMODULIN-BINDING PROTEINS; CIRCULATING TUMOR DNA; COLORECTAL NEOPLASMS; FEMALE; GENE FUSION; GENETIC TECHNIQUES; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 85024127675     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0376     Document Type: Article

References (36)

1. Giannakis M, Mu XJ, Shukla SA et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep 2016 [Epub ahead of print].
2. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
3. Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25: 1346-1355.
4. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl JMed 2013;369:1023-1034.
5. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-762.
6. Misale S, Di Nicolantonio F, Sartore-Bianchi A et al. Resistance to Anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-1280.
7. Rankin A, Klempner SJ, Erlich R et al. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. The Oncologist 2016 [Epub ahead of print].
8. Hurwitz H, Hainsworth JD, Swanton C et al. Targeted therapy for gastrointestinal (GI) tumors based on molecular profiles: Early results from My Pathway, an openlabel phase IIa basket study in patients with advanced solid tumors. J Clin Oncol 2016:34(suppl 4S; abstr 653).
9. Disel U, Germain A, Yilmazel B et al. Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. Oncoscience 2015;2: 581-584.
10. Moreira RB, Peixoto RD, de Sousa Cruz MR. Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Rep Oncol;8:83-87.
11. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18: 382-384.
12. Yakirevich E, Resnick MB, Mangray S et al. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. Clin Cancer Res 2016;22:3831-3840.
13. Houang M, Toon CW, Clarkson A et al. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2015;23:134-138.
14. Ying J, Lin C, Wu J et al. Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population. PLoS One 2015;10:e0144731.
15. Amatu A, Somaschini A, Cerea G et al.NovelCADALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer 2015;113:1730-1734.
16. Medico E, Russo M, Picco G et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 2015;6:7002.
17. Lee J, Kim HC, Hong JY et al. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget 2015;6:24320-24332.
18. Aisner DL, Nguyen TT, Paskulin DD et al. ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers. Mol Cancer Res 2014;12:111-118.
19. Lin E, Li L, Guan Y et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7: 1466-1476.
20. Stransky N, Cerami E, Schalm S et al. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846.
21. Hechtman JF, Zehir A, Yaeger R et al. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Mol Cancer Res 2016; 14:296-301.
22. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
23. Kelly LM, Barila G, Liu P et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014;111:4233-4238.
24. NCCN Guidelines Version 2.2016 Colon Cancer. 2016. Available at https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 20, 2016.
25. Sartore-Bianchi A, Trusolino L, Martino C et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wildtype, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, openlabel, phase 2 trial. Lancet Oncol 2016;17:738-746.
26. Takegawa N, Yonesaka K, Sakai K et al. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. Oncotarget 2016;7:3453-3460.
27. Rachiglio AM, Abate RE, Sacco A et al. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget 2016 [Epub ahead of print].
28. Zhou J, Chang L, Guan Y et al. Application of Circulating Tumor DNA as a Non-Invasive Tool forMonitoring the Progression of Colorectal Cancer. PLoS One 2016;11:e0159708.
29. Kasprzycka M, Marzec M, Liu X et al. Nucleophosmin/ anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A 2006; 103:9964-9969.
30. Gao J, Yin M, Zhu Y et al. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. BMC Cancer 2013; 13:471.
31. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl JMed 2013;368:2385-2394.
32. Camidge DR, Kono SA, Lu X et al. Anaplastic lymphoma kinase gene rearrangements in nonsmall cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6:774-780.
33. Le DT, Uram JN, Wang H et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-2520.
34. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-1920.
35. Johnson DB, Frampton GM, Rioth MJ et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res 2016;4:959-967.
36. Campesato LF, Barroso-Sousa R, Jimenez L et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget 2015;6:34221-34227.